InClin Pty Ltd. is pleased to announce the opening of our new office in Australia; located at 25 Berry Street – No. 210 – North Sydney, Australia.
The new office demonstrates InClin’s continued commitment and investment in having a strong and visible presence in the region. InClin and InClin Pty Ltd have seen exciting growth in 2017 and having this expansion will only strengthen our company and allow us to continue that momentum into 2018.
“This new location signals the continued growth and success of our regional office in Australia,” said Taylor Kilfoil, Chief International Officer and Co-Founder of InClin. “Having an established office here in Sydney will enable us to attract and retain the highly skilled and specialized talent needed to support our continued growth and the expansion of the services we can offer to our clients placing studies in this region.”
With office locations in centralized biotech and drug development hubs such as Australia and California, InClin will continue to operate as a leading CRO in the world’s strongest biopharma markets.
InClin is a full-service Contract Research Organization (CRO) with offices in the San Francisco Bay Area and Sydney, Australia. We are a single source provider of an integrated full suite of clinical development services from Phase 1 through Phase 4, including project management, clinical monitoring, site and contract management, vendor management, data management, biostatistics, programming, drug safety, medical monitoring, medical writing, QA inspection readiness, as well as strategic consulting services. For more information feel free visit our website or contact us at our email address below.